A Randomized Phase II Study of Patients with Locally Advanced Gastric or Gastro-Esophageal Adenocarcinoma Treated with Induction Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Adjuvant Intraperitoneal Floxuridine Followed By Prolonged Administration of Capecitabine.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Floxuridine (Primary) ; Capecitabine; Cisplatin; Irinotecan
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 08 Jan 2018 Biomarkers information updated
- 22 Aug 2012 Actual patient number changed from 6 to 8 as reported by ClinicalTrials.gov.
- 24 May 2011 Planned End Date changed from 1 Nov 2013 to 1 Nov 2015 as reported by ClinicalTrials.gov.